PE20060374A1 - FUSED HETEROCYCLIC KINASE INHIBITORS - Google Patents

FUSED HETEROCYCLIC KINASE INHIBITORS

Info

Publication number
PE20060374A1
PE20060374A1 PE2005000752A PE2005000752A PE20060374A1 PE 20060374 A1 PE20060374 A1 PE 20060374A1 PE 2005000752 A PE2005000752 A PE 2005000752A PE 2005000752 A PE2005000752 A PE 2005000752A PE 20060374 A1 PE20060374 A1 PE 20060374A1
Authority
PE
Peru
Prior art keywords
iloxi
triazin
fluorophenyl
thiourea
methoxy
Prior art date
Application number
PE2005000752A
Other languages
Spanish (es)
Inventor
Robert M Borzilleri
Zhong Chen
Tram N Huynh
Xiao Tao Chen
Zhen-Wei Cai
Kyoung S Kim
Wayne Vaccaro
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20060374A1 publication Critical patent/PE20060374A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I O II, DONDE R1 ES H, ALQUILO, CICLOALQUILO, FENILO, FLUOROFENILO, ENTRE OTROS; R2 ES H, HALOGENO, CIANO, NO2, ENTRE OTROS; B ES O, S, SO, ENTRE OTROS; V ES CH2, NH, ENTRE OTROS; W, X SON CADA UNO C, N; Y ES O, S, NH, N-HALOGENO; ENTRE OTROS; Z ES NH, CH2, ENTRE OTROS; n ES 0-4; A ES 6-METOXI-5-METIPIRROLO[2,1-f][1,2,4]TRIAZIN-4-ILOXI, 6-CLORO-1-METIL-1H-PIRAZOLO[3,4-d]PIRIMIDIN-4-ILOXI, 5-METILPIRROLO[2,1-f][1,2,4]TRIAZIN-6-CARBOXILATO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-(3-FLUORO-4-(6-METOXI-5-METILPIRROLO[2,1-f][1,2,4]TRIAZIN-4-ILOXI)FENIL)-3-(2-FENILACETIL)TIOUREA; 1-(3-FLUORO-4-(6-METOXI-5-METILPIRROLO[2,1-f][1,2,4]TRIAZIN-4-ILOXI)FENIL)-3-(2-(4-FLUOROFENIL)ACETIL)TIOUREA; 1-(4-(6-CLORO-1-METIL-1H-PIRAZOLO[3,4-d]PIRIMIDIN-4-ILOXI)-3-FLUOROFENIL)-3-(2-(4-FLUOROFENIL)ACETIL)TIOUREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD TIROSINA CINASA DE LOS RECEPTORES DEL FACTOR DE CRECIMIENTO TALES COMO C-MET, UTILES EN EL TRATAMIENTO DEL CANCERREFERS TO A COMPOUND OF FORMULA I OR II, WHERE R1 IS H, ALKYL, CYCLOALKYL, PHENYL, FLUOROPHENYL, AMONG OTHERS; R2 IS H, HALOGEN, CYANE, NO2, AMONG OTHERS; B IS O, S, SO, AMONG OTHERS; V IS CH2, NH, AMONG OTHERS; W, X ARE EACH C, N; Y IS O, S, NH, N-HALOGEN; AMONG OTHERS; Z IS NH, CH2, AMONG OTHERS; n IS 0-4; A ES 6-METHOXY-5-METHYROLO [2,1-f] [1,2,4] TRIAZIN-4-ILOXI, 6-CHLORO-1-METHYL-1H-PYRAZOLO [3,4-d] PYRIMIDIN-4 -YLOXY, 5-METHYLPYRROL [2,1-f] [1,2,4] TRIAZIN-6-CARBOXYLATE, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 1- (3-FLUORO-4- (6-METHOXY-5-METHYLPYRROL [2,1-f] [1,2,4] TRIAZIN-4-ILOXI) PHENYL) -3- (2-PHENYLACETILE ) THIOUREA; 1- (3-FLUORO-4- (6-METHOXY-5-METHYLPYRROLO [2,1-f] [1,2,4] TRIAZIN-4-ILOXI) PHENYL) -3- (2- (4-FLUOROPHENYL) ACETYL) THIOUREA; 1- (4- (6-CHLORO-1-METHYL-1H-PYRAZOLO [3,4-d] PYRIMIDIN-4-ILOXI) -3-FLUOROPHENYL) -3- (2- (4-FLUOROPHENYL) ACETYL) THIOUREA, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF THE TIROSINE KINASE ACTIVITY OF GROWTH FACTOR RECEPTORS SUCH AS C-MET, USEFUL IN THE TREATMENT OF CANCER

PE2005000752A 2004-06-28 2005-06-28 FUSED HETEROCYCLIC KINASE INHIBITORS PE20060374A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58345904P 2004-06-28 2004-06-28
US61256304P 2004-09-23 2004-09-23

Publications (1)

Publication Number Publication Date
PE20060374A1 true PE20060374A1 (en) 2006-05-07

Family

ID=35457856

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005000754A PE20060524A1 (en) 2004-06-28 2005-06-28 HETEROCICLIC FUSED COMPOUNDS AS INTERMEDIARIES IN THE PREPARATION OF KINASE INHIBITING PYRROLOTRIAZINES
PE2005000752A PE20060374A1 (en) 2004-06-28 2005-06-28 FUSED HETEROCYCLIC KINASE INHIBITORS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2005000754A PE20060524A1 (en) 2004-06-28 2005-06-28 HETEROCICLIC FUSED COMPOUNDS AS INTERMEDIARIES IN THE PREPARATION OF KINASE INHIBITING PYRROLOTRIAZINES

Country Status (14)

Country Link
US (2) US20050288290A1 (en)
EP (3) EP1771177A4 (en)
JP (3) JP4782117B2 (en)
KR (3) KR20070026621A (en)
AR (2) AR050254A1 (en)
AU (2) AU2005259894C1 (en)
BR (1) BRPI0512722A (en)
CA (1) CA2571680A1 (en)
IL (1) IL180325A0 (en)
MX (2) MXPA06015032A (en)
NO (3) NO20070453L (en)
PE (2) PE20060524A1 (en)
TW (2) TW200604184A (en)
WO (3) WO2006004636A2 (en)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US9169406B2 (en) * 2003-08-25 2015-10-27 Dow Global Technologies Llc Coating compositions
EP2612853A1 (en) * 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
DE10357510A1 (en) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroaryl-substituted benzenes
EP1719762B1 (en) 2004-02-27 2012-06-27 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (1)
EP2332940B1 (en) * 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
DE102004017438A1 (en) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituted phenylaminopyrimidines
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
ES2438017T3 (en) * 2004-07-30 2014-01-15 Methylgene Inc. VEGF receptor and HGF receptor signaling inhibitors
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US8875040B2 (en) * 2005-06-07 2014-10-28 Rockwell Automation Technologies, Inc. Universal web-based reprogramming method and system
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
US7470693B2 (en) * 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
CA2608726C (en) * 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (en) * 2005-05-20 2021-05-25 Methylgene Inc vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition
US7402582B2 (en) * 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7619083B2 (en) * 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8299252B2 (en) 2005-08-05 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Pyrazolopyridine and pyrrolopyridine multikinase inhibitors
WO2007023768A1 (en) 2005-08-24 2007-03-01 Eisai R & D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (3)
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP2009522363A (en) * 2006-01-04 2009-06-11 ローカス ファーマシューティカルズ、インク． Protein kinase inhibitors
JP2009529047A (en) * 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド Heterobicyclic pyrazole compounds and uses thereof
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
WO2007124332A1 (en) * 2006-04-21 2007-11-01 Bristol-Myers Squibb Company PROCESS FOR THE PREPARATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US20090306103A1 (en) * 2006-05-19 2009-12-10 Stephen Boyer Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US8778977B2 (en) * 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
ATE535520T1 (en) 2006-08-23 2011-12-15 Eisai R&D Man Co Ltd SALT OF A PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
WO2008046216A1 (en) * 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
EP2079738A2 (en) * 2006-10-27 2009-07-22 Glaxo Group Limited 7-azaindole derivatives as c-met kinase inhibitors
EP2089364B1 (en) * 2006-11-08 2013-06-12 Bristol-Myers Squibb Company Pyridinone compounds
CN101730699A (en) * 2007-03-21 2010-06-09 百时美施贵宝公司 Can be used for treating the condensed heterocyclic compouds of proliferative, allergy, autoimmunity and diseases associated with inflammation
RU2495044C2 (en) * 2007-08-29 2013-10-10 Метилджен Инк. Protein tyrosine kinase activity inhibitors
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
DE102007051762A1 (en) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituted pyrrolotriazines and their use
TW200924770A (en) 2007-11-06 2009-06-16 Astrazeneca Ab Novel compounds 089
WO2009061516A1 (en) 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
JP2009132660A (en) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd Composition for treating esophageal cancer
KR101596527B1 (en) * 2008-01-23 2016-02-22 브리스톨-마이어스 스큅 컴퍼니 4-pyridinone compounds and their use for cancer
WO2009094427A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
EP2262815A4 (en) * 2008-03-05 2012-04-11 Methylgene Inc Inhibitors of protein tyrosine kinase activity
JP2011513483A (en) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrimidines and pyridines useful as inhibitors of protein kinases
UY31982A (en) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
UY31984A (en) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF N-substituted 1- (3,4-difluorobenzyl) -6-oxo-1,6-dihydropyrimidin-5-carboxamides and 2- (3,4-difluorobenzyl) -3-oxo-2,3-dihydro- N-substituted 1H-pyrazol-4-carboxamides.
TWI365185B (en) * 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
KR100961410B1 (en) * 2008-10-14 2010-06-09 (주)네오팜 Heterocyclic compounds as protein kinases inhibitors
AR074830A1 (en) 2008-12-19 2011-02-16 Cephalon Inc PIRROLOTRIAZINAS AS ALK AND JAK2 INHIBITORS
TWI447108B (en) 2009-01-16 2014-08-01 Exelixis Inc Malate salts of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
US20120136033A1 (en) * 2009-05-18 2012-05-31 President And Fellows Of Harvard College Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof
ES2604667T3 (en) 2009-06-17 2017-03-08 Vertex Pharmaceuticals Incorporated Inhibitors of influenza virus replication
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
BR112012003462A2 (en) 2009-08-24 2016-02-23 Ascepion Pharmaceuticals Inc "compound, pharmaceutical composition, and method for treating a patient having a protein kinase mediated condition."
US8569319B2 (en) 2010-04-29 2013-10-29 Deciphera Pharmaceuticals, LLS Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
EA201690998A1 (en) 2010-05-17 2017-01-30 Инкозен Терапьютикс Пвт. Лтд. NEW CONNECTIONS OF 3,5-DESIGNED-3H-IMIDAZO [4,5-b] Pyridine and 3,5-DESIGNED-3H- [1,2,3] TRIAZOLO [4,5-b] Pyridine as modulators of protein kinase
MX2012014776A (en) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Antitumor agent using compounds having kinase inhibitory effect in combination.
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
US9283225B2 (en) * 2011-08-10 2016-03-15 Merck Patent Gmbh Pyrido-pyrimidine derivatives
BR112014024251A8 (en) 2012-03-30 2018-01-23 Rhizen Pharmaceuticals S A new 3,5-disubstituted pyridine-3h-imidazo [4,5-b] and 3,5-disubstituted pyridine -3h- [1,2,3] triazolo [4,5-b] as protein kinase modulators c-met
TWI520962B (en) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
WO2014115171A1 (en) * 2013-01-24 2014-07-31 Council Of Scientific & Industrial Research Triazine compounds and a process for preparation thereof
JP6411379B2 (en) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AU2014337314B2 (en) * 2013-10-17 2018-12-13 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
MX2016006200A (en) 2013-11-13 2016-08-08 Vertex Pharma Methods of preparing inhibitors of influenza viruses replication.
SG11201605207PA (en) * 2013-12-26 2016-07-28 Ignyta Inc Pyrazolo[1,5-a]pyridine derivatives and methods of their use
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
ES2926687T3 (en) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Highly pure quinoline derivative and method for its production
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
JP6617155B6 (en) 2015-04-07 2020-01-22 グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド Tyrosine kinase inhibitor and pharmaceutical composition containing the same
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2018059534A1 (en) * 2016-09-30 2018-04-05 广东众生药业股份有限公司 Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
CN110072865B (en) * 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
WO2018228923A1 (en) * 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
US11427578B1 (en) 2017-07-18 2022-08-30 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
TWI842978B (en) * 2018-07-13 2024-05-21 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
UY38349A (en) 2018-08-30 2020-03-31 Array Biopharma Inc PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
AR117472A1 (en) 2018-12-21 2021-08-11 Celgene Corp RIPK2 TIENOPYRIDINE INHIBITORS
FI3856341T3 (en) 2019-04-12 2023-11-30 Blueprint Medicines Corp Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
HRP20240702T1 (en) 2019-04-12 2024-08-16 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
CN110407839B (en) * 2019-07-01 2022-01-04 江西科技师范大学 Preparation and application of triazole heterocyclic compound containing heteroaryl amide structure
EP4005637A4 (en) * 2019-07-29 2023-07-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW202140426A (en) * 2020-02-14 2021-11-01 日商大鵬藥品工業股份有限公司 Analogous substances of acyl thiourea compound
CN113880845A (en) * 2021-10-13 2022-01-04 广州六顺生物科技股份有限公司 Pyrrolotriazine derivatives, and preparation method and application thereof
WO2023111996A1 (en) * 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646202A (en) 1967-11-22 1972-02-29 Merck & Co Inc Liver fluke compositions containing salicylic acid derivatives
JPS54115384A (en) 1978-02-28 1979-09-07 Hokko Chem Ind Co Ltd Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides
CH648611A5 (en) 1980-08-18 1985-03-29 Staeubli Ag METHOD AND DUMPING MACHINE FOR EQUALIZING ALL SHAFTS OF A WEAVING MACHINE.
GB2106500B (en) 1981-09-18 1986-01-02 Dow Chemical Co Method for making benzoylphenylureas
DE3139457A1 (en) 1981-10-03 1983-04-21 Bayer Ag, 5090 Leverkusen Novel substituted benzanilide ethers, processes for their preparation, their use as fungicides, and intermediates therefor
EP0119774B1 (en) 1983-03-09 1987-06-24 Beecham Group Plc Anti-inflammatory pyrazolo pyridines
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
US4663341A (en) 1984-02-16 1987-05-05 Rohm And Haas Company Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides
GB8404584D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
CH657015A5 (en) 1984-06-27 1986-08-15 Ciba Geigy Ag MUD AND COPPER PROTECTION AGENTS.
JPS6133176A (en) 1984-07-24 1986-02-17 Ishihara Sangyo Kaisha Ltd N-nitrobenzoyl-n'-pyridazinyloxyphenylurea compound, its preparation and carcinostatic agent containing said compound
US4753940A (en) 1985-02-15 1988-06-28 Ciba-Geigy Corporation Barbituric acid derivatives
JPS62135463A (en) 1985-12-09 1987-06-18 Ishihara Sangyo Kaisha Ltd N-benzoylurea compound, carcinostatic agent containing same and production thereof
JPS625959A (en) 1986-03-05 1987-01-12 Ishihara Sangyo Kaisha Ltd Benzoylurea compound
JPS625960A (en) 1986-03-05 1987-01-12 Ishihara Sangyo Kaisha Ltd Production of benzoylurea compound
JPS6262A (en) 1986-03-05 1987-01-06 Ishihara Sangyo Kaisha Ltd Production of benzoylurea compound
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
DE3830054A1 (en) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh PHENYLAMIDES - PROCESS FOR PRODUCING THE SAME AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
EP0420804A3 (en) 1989-09-26 1991-11-27 Ciba-Geigy Ag Anthelmintic compounds
SU1761753A1 (en) 1990-07-16 1992-09-15 Ф. С. Михайлицын и Н. С. Уварова 5[2-chloro-4-nitro(amino)phenoxy]-benzo-2,1,3-thiadiazole as an intermediate for synthesis of 5@@@(2-chloro-4- -[2-hydroxy-3,5-dibromobenzoyl)-amino]-phenoxy@@@-benzo- 2,1,3-thiadiazole showing activity against hymenolepiasis in white mice
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
JP4004066B2 (en) * 1995-11-01 2007-11-07 ノバルティス アクチエンゲゼルシャフト Purine derivatives and process for producing the same
DE69622183D1 (en) * 1995-11-07 2002-08-08 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLE DERIVATIVES, WHICH INHIBIT THE AUTOPHOSPHORYLATION OF THE GROWTH FACTOR RECEPTOR DERIVING FROM BLOOD PLATPLES AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE19710609A1 (en) 1997-03-14 1998-09-17 Bayer Ag Substituted aminosalicylic acid amides
BR9810508A (en) 1997-07-03 2000-09-05 Du Pont Pharm Co Compound, pharmaceutical composition and method of treating a disorder
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
TW515786B (en) 1997-11-25 2003-01-01 Nihon Nohyaku Co Ltd Phthalic acid diamide derivatives, agricultural and horticultural insecticides, and a method for application of the insecticides
US6362369B2 (en) 1997-11-25 2002-03-26 Nihon Nohyaku Co., Ltd. Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides
JP4253126B2 (en) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド PPAR-gamma modulator
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ299375B6 (en) 1998-11-30 2008-07-09 Nihon Nohyaku Co., Ltd. Phthalimide derivatives or salts thereof, agricultural- horticultural insecticidal agent and application method thereof
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ES2208261T3 (en) 1999-01-22 2004-06-16 Kirin Beer Kabushiki Kaisha DERIVATIVES OF QUINOLINA AND DERIVATIVES OF QUINAZOLINA.
DE60006649T2 (en) 1999-02-22 2004-09-30 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) C-21 MODIFIED EPOTHILONE
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
MXPA01011832A (en) 1999-05-21 2002-06-21 Squibb Bristol Myers Co Pyrrolotriazine inhibitors of kinases.
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PL206415B1 (en) 1999-07-20 2010-08-31 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
KR100531990B1 (en) 1999-09-24 2005-12-02 니혼노야쿠가부시키가이샤 Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
AU2576501A (en) 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
EP1243582A4 (en) 1999-12-24 2003-06-04 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
WO2001094353A1 (en) 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
FR2812633A1 (en) 2000-08-04 2002-02-08 Aventis Cropscience Sa PHENYL (THIO) UREA AND PHENYL (THIO) CARBAMATE FUNGICIDES DERIVATIVES
KR100600550B1 (en) 2000-10-20 2006-07-13 에자이 가부시키가이샤 Nitrogenous aromatic ring compounds
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
JP2004522713A (en) 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー Method for treating p38 kinase-related diseases and pyrrolotriazine compounds useful as kinase inhibitors
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
CN1289072C (en) 2000-12-22 2006-12-13 石原产业株式会社 Aniline derivatives or salts thereof and cytokine prodn inhibitors contg. same
EP1490362A2 (en) * 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
CN100415720C (en) 2001-06-22 2008-09-03 麒麟医药株式会社 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
SE0102384D0 (en) 2001-07-03 2001-07-03 Pharmacia Ab New compounds
WO2003011028A1 (en) 2001-08-01 2003-02-13 Nissan Chemical Industries, Ltd. Substituted amides and pest controllers
EP1447405A4 (en) 2001-10-17 2005-01-12 Kirin Brewery Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US20050038035A1 (en) * 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
ES2275931T5 (en) * 2001-12-03 2018-10-23 Bayer Healthcare Llc Aryl urea compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers
JP2003321472A (en) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk inhibitor
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
EP1503996B1 (en) 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
DK1497019T3 (en) * 2002-04-23 2015-08-03 Bristol Myers Squibb Co PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TWI272271B (en) * 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
US6951859B2 (en) 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN1771234A (en) 2003-02-05 2006-05-10 布里斯托尔-迈尔斯斯奎布公司 Process for preparing pyrrolotriazine kinase inhibitors
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DE10357510A1 (en) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroaryl-substituted benzenes
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds

Also Published As

Publication number Publication date
AU2005260056B2 (en) 2009-08-27
EP1768983A2 (en) 2007-04-04
JP2008504368A (en) 2008-02-14
JP4860609B2 (en) 2012-01-25
NO20070514L (en) 2007-03-12
KR20070026621A (en) 2007-03-08
AR050254A1 (en) 2006-10-11
TW200604184A (en) 2006-02-01
WO2006004833A3 (en) 2006-07-13
WO2006004884A3 (en) 2006-03-23
AR049536A1 (en) 2006-08-09
AU2005260056A1 (en) 2006-01-12
CA2571680A1 (en) 2006-01-12
EP1771177A2 (en) 2007-04-11
MXPA06015192A (en) 2007-02-28
AU2005259894B2 (en) 2009-03-19
WO2006004636A2 (en) 2006-01-12
EP1771177A4 (en) 2009-07-29
JP2008504367A (en) 2008-02-14
AU2005259894C1 (en) 2009-09-17
KR20070037448A (en) 2007-04-04
NO20070506L (en) 2007-02-14
TW200607505A (en) 2006-03-01
WO2006004884A2 (en) 2006-01-12
WO2006004636A3 (en) 2006-05-26
US20060004006A1 (en) 2006-01-05
US7173031B2 (en) 2007-02-06
KR20070028458A (en) 2007-03-12
MXPA06015032A (en) 2007-02-08
EP1761268A4 (en) 2009-07-08
EP1761268A2 (en) 2007-03-14
IL180325A0 (en) 2007-07-04
NO20070453L (en) 2007-01-24
JP4782117B2 (en) 2011-09-28
AU2005259894A1 (en) 2006-01-12
PE20060524A1 (en) 2006-06-21
US20050288290A1 (en) 2005-12-29
BRPI0512722A (en) 2008-04-01
WO2006004833A2 (en) 2006-01-12
JP2008504366A (en) 2008-02-14

Similar Documents

Publication Publication Date Title
PE20060374A1 (en) FUSED HETEROCYCLIC KINASE INHIBITORS
RU2386622C2 (en) Heteroaromatic derivatives of urea and use thereof as glucokinase activators
PE20060197A1 (en) BICYCLE HETEROCYCLES AS KINASE INHIBITORS
PE20050681A1 (en) PYRID [2,3-d] PYRIMIDINE-2,4-DIAMINES AS INHIBITORS OF PDE 2
PE20081845A1 (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
AR056691A1 (en) PIRROLOPIRIMIDINE DERIVATIVES AS SYK INHIBITORS
PE20090617A1 (en) AMINO-5 - [- 4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF -SECRETASE
PE20080677A1 (en) PYRROLOTRIAZINE INHIBITORS CINAZA
CO5580778A2 (en) LACTAMA DERIVATIVES AS ANTAGONISTS FOR 11CB AND HUMAN RECEPTORS
PE20050691A1 (en) PROCESS TO PREPARE 2-AMINOTIAZOL-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS
PE20120305A1 (en) HETEROCICLIC COMPOUNDS DERIVED FROM BENZOTHIAZOLE AND TETRAHYDROQUINOLINE AS INHBIDERS OF BCL-2 AND BCL-XL
PE20060600A1 (en) AMINOPYRIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF AURORA TO KINASE
EA200600315A1 (en) Pyrimidine compounds, their use as a-selective antagonists and a way to obtain them
PE20051171A1 (en) PROTEIN INHIBITORS KINASES WITH 3-QUINOLINE CARBONITRILE STRUCTURE
PE20070855A1 (en) DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
PE20121506A1 (en) TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
AR062125A1 (en) COMPOUNDS THAT MODULATE THE CB2 RECEIVER AND ITS USE AS MEDICATIONS
PE20050132A1 (en) SUBSTITUTED HETEROCYCLIC PIPERAZINES
PE20051046A1 (en) DIARYL-UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES
PE20060625A1 (en) BENZAZEPINE DERIVATIVES AS ANTAGONISTS AND / OR AGONISTS OF THE HISTAMINE H3 RECEPTOR
AR051485A1 (en) PIRAZOLO PIRIMIDINAS 1,4-REPLACED AS QUINASE INHIBITORS
PE20060383A1 (en) NEW CYCLIC UREA AMINO DERIVATIVES AS KINASE INHIBITORS
PE20040647A1 (en) TYROSINE KINE INHIBITORS
ES2314418T3 (en) DERIVATIVES OF AMIDAS OF THE ACID 4-BROMO-5- (2-CHLOROBENZOYLAMINE) -1H-PIRAZOL-3-CARBOXYCLIC AND RELATED COMPOUNDS AS ANTIGONISTS OF THE B1 BRADIQUININE RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES.
PE20121510A1 (en) ISOQUINOLINONES AND SUBSTITUTE QUINAZOLINONES

Legal Events

Date Code Title Description
FD Application declared void or lapsed